Carcinoma of the Corpus Uteri

Creasman, William T.; Odicino, Franco; Maisonneuve, Patrick; Quinn, Michael; Beller, U.; Benedet, J.L.; Heintz, A.P.M.; Ngan, Hextan Y.S.; Pecorelli, Sërgio

doi:10.1016/s0020-7292(06)60031-3

Cited by 820 publications

(306 citation statements)

References 0 publications

Supporting

Mentioning

290

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, approximately 16% of cases are identified with either stage III or IV disease [2] with 5-year survival rates ranging from 30–89% [3,4,5] and 0–10% [6], respectively. Moreover, after primary diagnosis and treatment, roughly 30–40% of patients with stage III and IV are expected to recur within the subsequent 5 years [7]. …”

Section: Introductionmentioning

confidence: 99%

Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study

et al. 2011

View full text Add to dashboard Cite

Objectives: Adjuvant treatment for stage III endometrial cancer is not yet defined. Previous experiences support the usefulness of combined chemotherapy and radiotherapy. The aim of this retrospective study was to describe the outcome in a cohort of patients with stage III endometrial cancer treated with chemotherapy and/or radiotherapy. Methods: A multicenter retrospective analysis of patients with stage III endometrial cancer from 1998 to 2009 was conducted. The impact on relapse-free survival of clinical and pathological variables and adjuvant treatment received was analyzed by univariate and multivariate analysis. Results: Eighty-two patients were considered. Median age was 62 years (range 38–82). Seventy-eight (95%) patients received an adjuvant treatment: chemotherapy (41; 50%), radiotherapy (18; 22%), or combined chemo-radiotherapy (19; 23%). Four patients were excluded from analysis because they were not treated with any adjuvant therapy. At univariate analysis, tumor grade (G3 vs. G1–G2; p = 0.003) was associated with risk of recurrence; similarly, patients treated with radiotherapy alone (p = 0.031, hazard ratio 0.19, 95% CI 0.04–0.86) or chemotherapy alone (p = 0.053, hazard ratio 0.54, 95% CI 0.29–1.01) had a significantly higher risk for relapse, compared to those treated with the multimodality approach. Relapse-free survival at 3 years was 86.5, 65.8 and 44.1%, with the multimodality approach, chemotherapy and radiotherapy, respectively. At multivariable analysis, age and grading were independently associated with recurrence-free survival. Hazard ratio for relapse-free survival was 0.14 (95% CI 0.02–1.04) and 0.20 (95% CI 0.04–1.11) for multimodality treatment compared to chemotherapy alone and radiotherapy alone, respectively. Conclusions: Age and grading are independent prognostic factors. A combined approach with radiotherapy and chemotherapy may induce an advantage in relapse-free survival compared to radiotherapy or chemotherapy alone. Prospective clinical trials are needed to verify this clinical hypothesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Their 5-year survival is approximately 83%. 22 By contrast, the average age of patients with nonendometrioid cancer is 67 years. And, at least half have already spread beyond the corpus at the time of diagnosis.…”

Section: Menopause and Endometrial Cancermentioning

confidence: 99%

“…Their 5-year survival is approximately 62% for clear cell carcinoma and 53% for papillary serous cancers. 22 Most endometrial carcinomas are diagnosed at an early stage and have a good prognosis. The most common presenting symptom is postmenopausal bleeding.…”

Section: Menopause and Endometrial Cancermentioning

confidence: 99%

Menopause and Gynecological Malignancy

Ferdous¹,

Khatun²

2013

Journal of SAFOMS

View full text Add to dashboard Cite

Menopause is a consequence of biological aging. Menopause does not cause cancer, but the risk of developing cancer increase as a woman ages. Treatment of cancer can also cause premature menopause. Among the gynecological cancer, cervical cancer tops the list of common cancer. Postmenopausal women are prone to have persistent human papillomavirus (HPV) infection. There is no role of primary prevention of cervical cancer by vaccination in postmenopausal women. Secondary prevention by Paps smear only may provide false negative result as the cervix is often flushed with the vagina. So, scraping by Ayres spatula and using endometrial brush is necessary in these women. Unfortunately, symptoms of cervical cancer in postmenopausal women are nonspecific and associated with comorbidities. So, any symptom of cervical cancer in postmenopausal women should be properly evaluated. Ovarian cancer is the number one cancer of death among all gynecologic malignancies. Majority of the ovarian cancer in postmenopausal women present with vague symptom and have the advance stage at prevention. Currently, no reliable screening test is available. Yearly routine pelvic examination, transvaginal ultrasonography and serum CA-125 can be performed in selective high-risk women only. Endometrial cancer is the most common gynecologic cancer in the USA. Most endometrial carcinomas are diagnosed at an early stage and have a good prognosis. Though vulvar and vaginal cancer are rare malignancies, yet these are prevalent in postmenopausal women. Any postmenopausal women with long-term intense itching, pervaginal discharge or any ulcer of vulva or vagina should be evaluated properly.

show abstract

“…Most cases are diagnosed while in stage I, limited to the uterus. Fiveyear survival rate after surgery is very high, 88% [3].…”

Section: Introductionmentioning

confidence: 99%

Laparoscopic versus laparotomy approach to endometrial cancer: A prospective study

Carlos¹,

Martín-Francisco²,

Ángel³

et al. 2013

OJOG

View full text Add to dashboard Cite

Objective: The aim of this study was to compare laparoscopic (LPS) and laparotomy (LPT) approaches for endometrial cancer, and to assess intraoperative and postoperative results, disease-free survival and overall survival. Methods: We designed a prospective observational study, every patient diagnosed of endometrial cancer and subsidiary to surgical staging was included. Total hysterectomy, bilateral adnexectomy, pelvic lymphadenectomy were performed in every case. Paraaortic lymphadenectomy was performed depending on tumor histology. Results: 70 patients with endometrial cancer were enrolled, 49 (70%) were treated laparoscopically and 21 (30%) laparotomically. There was not statistical significant difference in the mean operative time, it was 183.06 ± 21.03 min (range 120 -230) in the LPS group and 195.24 ± 28.39 min (range 130 -240) in the LPT group, mean difference 12.16 (95% CI −0.2 -24). There was no difference in the number of lymph nodes resected. Mean blood loss was lower in the LPS group. There were less postoperative complications, 3 (6.12%) in the LPS group and 7 (33.3%) in the LPT group (p < 0.01). Mean hospital stay was significantly shorter in the LPS group 4.29 ± 1.62 days vs 8.81 ± 3.37 days in the LPT group (p < 0.01), mean difference 4.52 (95% CI 3.3 -5.7). Overall survival was similar in both groups. Conclusion: Laparoscopic approach for endometrial cancer offers similar results in terms of survival and oncological radicality as the laparotomic approach and a lower rate of complications, a quicker convalescence time and a shorter hospital stay.

show abstract

Carcinoma of the Corpus Uteri

Cited by 820 publications

References 0 publications

Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study

Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study

Menopause and Gynecological Malignancy

Laparoscopic versus laparotomy approach to endometrial cancer: A prospective study

Contact Info

Product

Resources

About